Nine Masts Capital’s Lineage Cell Therapeutics LCTX Stock Holding History

Nine Masts Capital’s Portfolio LCTX Stock Details LCTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-29,194	Closed	-$46.1K	–	242
2026 Q1	$46.1K	Buy	+29,194	New	+$49.2K	0.01%	148

Other funds holding LCTX

Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return

Fifth Third Bancorp Cincinnati, Ohio $61.7B AUM 33.76% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Nine Masts Capital's LCTX Position: Q2 2026 in Review

Nine Masts Capital sold out of Lineage Cell Therapeutics (LCTX) in Q2 2026, closing a stake of 29,194 shares — an estimated $46.1K sold.

Nine Masts Capital first reported a position in LCTX in Q1 2026 and held it in 1 quarter. The position peaked at $46.1K in Q1 2026. 132 funds tracked by Wall St. Rank hold LCTX as of Q2 2026.

Nine Masts Capital reported no remaining Lineage Cell Therapeutics position as of Q2 2026 after selling out during the quarter.
Nine Masts Capital sold 29,194 Lineage Cell Therapeutics shares in Q2 2026, an estimated $46.1K.
Nine Masts Capital first reported a position in Lineage Cell Therapeutics in Q1 2026 and held it in 1 quarter.
Nine Masts Capital's Lineage Cell Therapeutics position peaked at $46.1K in Q1 2026.
132 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2026.

Based on Nine Masts Capital's 13F filing for Q2 2026, filed 7 Aug 2026.